Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: Presentation of a case and review of the literature

Cancer Investigation

Volumn 24, Issue 3, 2006, Pages 283-287

  Brandes, Johann C ^a,b   Grossman, Stuart A ^a   Ahmad, Homaa ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Effusion; Mesothelioma; Non small cell lung cancer (NSCLC); Pemetrexed; Toxicity

Indexed keywords

CARBOPLATIN; CARBOXYPEPTIDASE G2; CISPLATIN; CREATININE; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; METHOTREXATE; PEMETREXED; TETRAHYDROFOLIC ACID; THYMIDINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ASCITES; ASCITES FLUID; CANCER RADIOTHERAPY; CASE REPORT; CREATININE BLOOD LEVEL; DRUG ACCUMULATION; DRUG EXCRETION; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPHADENECTOMY; MALE; PARACENTESIS; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; URINARY EXCRETION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITIC FLUID; CISPLATIN; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; KIDNEY FAILURE, ACUTE; LEUCOVORIN; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION; PLEURAL NEOPLASMS; RENAL DIALYSIS; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 33646485695     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600629567     Document Type: Article

References (21)

1. Vogelzang, N.J.; Rusthoven, J.J.; Symanowski, J.; Denham, C.; Kaukel, E.; et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J. Clin. Oncol. 2003, 21 (14), 2636-2644.
2. Hanna, N.; Shepherd, F.A.; Fossella, F.V.; Pereira, J.R.; De Marinis, F.; et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004, 22 (9), 1589-1597.
3. Martin, M.; Spielmann, M.; Namer, M.; duBois, A.; Unger, C.; et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann. Oncol. 2003, 14 (8), 1246-1252.
4. John, W.; Picus, J.; Blanke, C.D.; Clark, J.W.; Schulman, L.N.; et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000, 88 (8), 1807-1813.
5. Bajetta, E.; Celio, L.; Buzzoni, R.; Ferrari, L.; Marchiano, A.; et al. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann. Oncol. 2003, 14 (10), 1543-1548.
6. Shih, C.; Chen, V.J.; Gossett, L.S.; Gates, S.B.; MacKellar, W.C.; et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997, 57 (6), 1116-1123.
7. Zhao, R.; Babani, S.; Gao, F.; Liu, L.; Goldman, I.D. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin. Cancer Res. 2000, 6 (9), 3687-3695.
8. Mendelsohn, L.G.; Shih, C.V.; Chen, J.; Habeck, L.L.; Gates, S.B.; Shackelford, K.A.; Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin. Oncol. 1999, 26 (2 Suppl 6), 42-47.
9. Rinaldi, D.A.; Kuhn, J.G.; Burris, H.A.; Dorr, F.A.; Rodriguez, G.; et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 1999, 44 (5), 372-380.
10. Chaudhary, A.K.; Schannen, V.; Knadler, M.P.; Lantz, R.; Le Lacheur, R.M. Analysis of LY231514 in plasma and urine using perchloric acid with LC/MS/MS. Proceedings of the 47th ASMS Conference on Mass Spectrometry and Allied Topics, June 1999, Dallas, Texas, USA, 1999.
11. Shih, C.; Habeck, L.L.; Mendelsohn, L.G.; Chen, V.J.; Schultz, R.M. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv. Enzyme Regul. 1998, 38, 135-152.
12. McDonald, A.C.; Vasey, P.A.; Adams, L.; Walling, J.; Woodworth, J.R.; et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 1998, 4 (3), 605-610.
13. Gandara, D.R.; Edelman, M.J.; Crowley, J.J.; Lau D.H.; Livingston, R.B. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother. Pharmacol. 1997, 41 (1), 75-78.
14. Saland, J.M.; Leavey, P.J.; Bash, R.O.; Hansch, E.; Arbus, G.S.; Quigley, R. Effective removal of methotrexate by high-flux hemodialysis Pediatr. Nephrol. 2002, 17(10)825-829. Epub 2002 Aug 9.
15. Mohty, M.; Peyriere, H.; Guinet, C.; Hillaire-Buys, D.; Blayac, J.P.; Rossi, J.F. Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure. Leuk. Lymphoma. 2000, 37, (3-4), 441-443.
16. Krackhardt, A.; Schwartz, S.; Korfel A.; Thiel, E. Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure. Leuk. Lymphoma. 1999, 35 (5-6), 631-635.
17. Widemann, B.C.; Balis, P.M.; Kempf-Bielack, B.; Bielack, S.; Pratt, C.B.; et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 2004, 100 (10), 2222-2232.
18. Goldman, I.D.; Zhao, R. Molecular, biochemical, and cellular pharmacology of pemetrexed Semin. Oncol. 2002, 29 (6 Suppl 18), 3-17.
19. Widemann, B.C.; Balis, P.M.; Murphy, R.F.; Sorensen, J.M.; Montello, M.J.; et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction J. Clin. Oncol. 1997, 15 (5), 2125-2134.
20. Castro, M. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure J. Clin. Oncol. 2003, 21 (21), 4066.
21. Curtin, N.J.; Hughes, A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2001, 2 (5), 298-306.